RARE — Ultragenyx Pharmaceutical Inc.
7 mentions in the last 24 hours · 0.03% of all mentions
Why people talked about RARE (2026-11-04)
- Ultragenyx reported Q3 2026 results with an EPS of -$1.16 and revenue of $173.0M, both missing estimates.
- The company is winding down GTX-102 studies for Angelman syndrome following a Phase 3 miss.
- The UX701 Cyprus2+ dose-finding program was terminated as data did not meet advancement criteria.
| Bluesky | 5 | community |
| GDELT | 1 | news |
| SEC EDGAR 8-K | 1 | filings |